Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment?
Rolfy A Perez HolguinElizabeth J OleckiKelly A StahlWilliam G WongCharles C ViningMatthew E B DixonJune S PengPublished in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2022)
This analysis suggests that cT2N0 esophageal and GEJ adenocarcinomas may not benefit from the intensive multimodality therapy utilized in locally advanced disease. Selective use of AT for patients who are upstaged pathologically, or have high-risk features, is associated with improved outcomes.
Keyphrases
- locally advanced
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- rectal cancer
- neoadjuvant chemotherapy
- computed tomography
- prognostic factors
- peritoneal dialysis
- radiation therapy
- clinical trial
- stem cells
- magnetic resonance imaging
- metabolic syndrome
- magnetic resonance
- combination therapy
- weight loss
- study protocol
- smoking cessation
- data analysis